Will FirstString’s Granexin Break the Dry Spell of Unsuccessful Diabetic Foot Ulcer Clinical Trials?
22 Dec 2016
Diabetic foot ulcers (DFUs) are a common complication of diabetes, and with the increasing prevalence of diabetes across all markets, the number of patients suffering from DFUs is also expected to rise. Despite the availability of various treatment modalities, there are currently few advanced wound care products available to treat hard-to-heal chronic wounds. For approximately two decades, the recombinant human growth factors Smith & Nephew’s Regranex (becaplermin), which is marketed in the US, and Kaken’s Fiblast (trafermin), which is marketed in Japan, have been the only pharmacologic wound-healing agents available. In addition, cell-based skin substitutes are used by foot care specialists to treat DFUs. The use of these cell-based therapies remains limited, however, due to their high cost. As a result, debridement, wound surface cleaning, dressings, off-loading, treatment of infection, and the consideration of revascularization in ischemic DFUs remain the most common management approach.
Registering for our Expert Insights is free and only takes a moment.
Following this you'll gain unlimited access to all of the latest, event-driven opinion
put together by our teams of experienced analysts.